Orphan Drugs for Cancer Pipeline Analysis

A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed for treating rare cancer diseases like solid tumor of the pancreas and thyroid, blood cancer, melanoma, and others.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Orphan-Drugs-for-Cancer-Pipeline-Analysis

“Orphan Drugs for Cancer Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed for the treatment of multiple cancers. Research report covers all the ongoing vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the market for orphan designated cancer drugs based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Detailed Therapeutic Trials

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Orphan Designated Drugs for Cancer Treatment by Clinical Development Phase:

• Preclinical: 11

• Phase-I: 25

• Phase-I/II: 33

• Phase-II: 68

• Phase-II/III: 6

• Phase-III: 41

• Preregistration: 8

• Registered: 3

• Marketed: 59

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.